Blackstone Inc’s Crescent Biopharma CBIO Stock Holding History

Blackstone Inc’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	+62,647	New	+$1.22M	﹤0.01%	241
2026 Q1	–	Sell	-75,614	Closed	-$897K	–	451
2025 Q4	$897K	Hold	75,614	–	–	﹤0.01%	225
2025 Q3	$899K	Hold	75,614	–	–	﹤0.01%	209
2025 Q2	$1.22M	Buy	+75,614	New	+$1.6M	0.01%	118
2015 Q1	–	Sell	-166	Closed	-$119K	–	61
2014 Q4	$119K	Buy	+166	New	+$130K	﹤0.01%	53

Other funds holding CBIO

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

NCM

NEXTBio Capital Management Menlo Park, California $217M AUM

Blackstone Inc's CBIO Position: Q2 2026 in Review

Blackstone Inc opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 62,647 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #241 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in CBIO as recently as Q4 2025.

Blackstone Inc first reported a position in CBIO in Q4 2014 and has held it in 5 quarters since. The position peaked at $1.22M in Q2 2025. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Blackstone Inc held 62,647 shares of Crescent Biopharma worth $1.13M as of Q2 2026.
Crescent Biopharma was a new Blackstone Inc position in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #241 holding.
Blackstone Inc first reported a position in Crescent Biopharma in Q4 2014 and has held it in 5 quarters since.
Blackstone Inc's Crescent Biopharma position peaked at $1.22M in Q2 2025.
70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.